We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Consortium Completes HapMap

By Biotechdaily staff writers
Posted on 02 Nov 2005
Phase I of a new tool called HapMap, which will speed the discovery of genes for common diseases, has been completed by more than 200 researchers from Canada, China, Japan, Nigeria, the United Kingdom, and the United States.

The results, reported in the October 27, 2005, issue of Nature, provide overwhelming evidence that variation in the human genome is organized into local neighborhoods, called haplotypes, which are usually inherited as intact blocks of information. More...
The HapMap consists of more than one million markers of genetic variation, or single nucleotide polymorphisms (SNPs). The same group is nearing completion of the Phase II HapMap, which will contain nearly three times more markers than the initial version.

The International HapMap Consortium (Salt Lake City, UT, USA; www.hapmap.org) produced the HapMap using DNA from blood samples collected from 269 volunteers from widely distributed geographical regions. Specifically, the samples came from Yoruba residents in Ibadan, Nigeria; Japanese residents in Tokyo, Japan; Han Chinese residents in Beijing, China; and Utah (USA) residents with ancestry from northern and western Europe.

Genetic diversity in humans is increased by recombination, which is the swapping of DNA from the maternal and paternal lines. By analyzing the HapMap data, researchers have produced a genome-wide inventory of where recombination takes place. The HapMap shows neighborhoods of correlated genetic variation, or haplotypes, across the entire human genome.

"The HapMap is a phenomenal tool that is making possible research that was impractical, if not unimaginable, only a few years ago,” said Yusuke Nakamura, M.D., Ph.D., director of the University of Tokyo's Human Genome Center who also worked on the HapMap. "It offers the scientific community an enormous savings, reducing the expense of searching the genome for hereditary factors in common disease by a factor of 10 to 20.”






Related Links:
HapMap

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.